Please check your internet connection and try again.
# Tamsulosin
## Overview
Tamsulosin is an alpha-1 adrenergic antagonist selective for alpha-1A and alpha-1D receptors primarily found in the prostate, bladder neck, and urethra.
## Primary Indications
* Symptomatic benign prostatic hyperplasia (BPH).
* Facilitation of ureteral stone passage (off-label in some regions).
## Adult Dosing
* **BPH:** 0.4 mg orally once daily. May increase to 0.8 mg orally once daily after 4 weeks if patient has not responded adequately.
* **Ureteral Stone Passage (off-label):** 0.4 mg to 0.8 mg orally once daily. The optimal duration is not well established and often depends on stone size and location.
## Pediatric Dosing
Tamsulosin is not indicated for use in pediatric patients for BPH. Efficacy and safety for other indications in pediatrics have not been established.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is typically required for mild to moderate renal impairment. Caution is advised in severe renal impairment, though specific dose adjustments are not defined.
* **Hepatic Impairment:** No dose adjustment is typically required for mild to moderate hepatic impairment. Use with caution in severe hepatic impairment as tamsulosin is metabolized by the liver.
## Contraindications
* Known hypersensitivity to tamsulosin or its components.
* History of angioedema related to tamsulosin.
* Concomitant use with other alpha-1 blockers (unless specific off-label use warrants it under close supervision).
## Adverse Effects
Common adverse effects include dizziness, abnormal ejaculation (including retrograde ejaculation and ejaculatory failure), orthostatic hypotension, headache, rhinitis, and fatigue.
## Key Drug Interactions
* **Other Alpha-1 Blockers:** Additive risk of hypotension.
* **CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir, cimetidine):** May increase tamsulosin exposure. Use with caution.
* **Antihypertensives:** Potential for additive hypotensive effects.
* **PDE-5 Inhibitors:** Use with caution due to potential for additive hypotensive effects.
## Monitoring
* Blood pressure (especially orthostatic changes).
* Symptoms of BPH (urinary flow rate, nocturia, frequency, urgency).
* Signs of angioedema.
* Assess for effectiveness in stone passage when used off-label.
## Clinical Pearls
* Administer tamsulosin 30 minutes after the same meal each day to ensure consistent absorption.
* Due to selective alpha-1A blockade, it may cause less orthostatic hypotension compared to non-selective alpha-1 blockers, but it can still occur.
* Prostate cancer screening should be performed routinely in men aged 55 years or older, or earlier based on risk factors, before initiating tamsulosin for BPH. Tamsulosin can mask rising PSA levels that may be indicative of prostate cancer.
* Dizziness or lightheadedness can increase the risk of falls, particularly in the elderly. Advise patients to stand up slowly.
***
*Disclaimer: This information is intended for clinical use and is not a substitute for professional medical judgment. Always consult the most current prescribing information and relevant literature for complete details, contraindications, and monitoring guidelines before making any treatment decisions. Local protocols may influence specific dosing or management strategies.*
